IP Library › Granted Patent US 7,097,823
Granted Patent B2
US 7,097,823 · App. 10/784,476 · Granted Aug 29, 2006

High dose radionuclide complexes for bone marrow suppression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,097,823
App. No.
10/784,476
Granted
Aug 29, 2006
Kind
B2
Abstract

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Claims (11)

1. A method for the treatment of osteomyelitis comprising:

administering a composition comprising a ligand-complexed radionuclide to a subject suffering from osteomyelitis under conditions such that said osteomyelitis is reduced.

2. The method of claim 1 wherein the ligand is a bone-targeting ligand.

3. The method of claim 2 wherein said ligand is a macrocylic aminophosphonic acid.

4. The method of claim 3 , wherein said ligand is 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid (DOTMP).

5. The method of claim 2 , wherein said ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, methylene diphosphonate, hydroxymethylenediphosphonate, hydroxyethylidene diphosphonate, and ethane-1-hydroxy-1,1-diphosphonic acid.

6. The method of claim 5 , wherein said ligand is ethylenediaminetetramethylenephosphonic acid.

7. The method of claim 1 , wherein said radionuclide is selected from the group consisting of Arsenic-77, Molybdenum-99, Rhodium-105, Lutetium-177, Cadmium-115, Antimony-122, Promethium-149, Osmium-193, Gold-198, Thorium-200, Samarium-153, Yttrium-90, Gadolinium-159, Rhenium-186, Rhenium-188, and Holmium-166.

8. The method of claim 4 wherein the ligand-complexed radionuclide is 166 Ho-DOTMP.

9. The method of claim 1 wherein the ligand-complexed radionuclide is administered by injection.

10. The method of claim 1 wherein the ligand is administered by infusion.